Dual GIP/GLP-1 receptor agonist with superior weight reduction outcomes vs semaglutide alone.
Corresponds to amino acids 176–191 of the human growth hormone molecule. It is studied for the fat-metabolism portion of GH activity, separated from the growth-promoting and glucose effects associated with full-length GH.
Active ingredient in Mounjaro and Zepbound. SURMOUNT-1 trial showed ~22% average body weight loss — significantly higher than semaglutide's ~15%.
The GIP component may contribute to improved tolerability, with some researchers reporting fewer GI side effects than pure GLP-1 agonists. GIP receptors are also expressed in bone and may have additional metabolic effects.